Back to Search Start Over

Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging-A prospective trial.

Authors :
Wagner, Lars M.
Kremer, Nathalie
Gelfand, Michael J.
Sharp, Susan E.
Turpin, Brian K.
Nagarajan, Rajaram
Tiao, Gregory M.
Pressey, Joseph G.
Yin, Julie
Dasgupta, Roshni
Source :
Cancer (0008543X); Jan2017, Vol. 123 Issue 1, p155-160, 6p
Publication Year :
2017

Abstract

<bold>Background: </bold>Lymph node metastases are an important cause of treatment failure for pediatric and adolescent/young adult (AYA) sarcoma patients. Nodal sampling is recommended for certain sarcoma subtypes that have a predilection for lymphatic spread. Sentinel lymph node biopsy (SLNB) may improve the diagnostic yield of nodal sampling, particularly when single-photon emission computed tomography/computed tomography (SPECT-CT) is used to facilitate anatomic localization. Functional imaging with positron emission tomography/computed tomography (PET-CT) is increasingly used for sarcoma staging and is a less invasive alternative to SLNB. To assess the utility of these 2 staging methods, this study prospectively compared SLNB plus SPECT-CT with PET-CT for the identification of nodal metastases in pediatric and AYA patients.<bold>Methods: </bold>Twenty-eight pediatric and AYA sarcoma patients underwent SLNB with SPECT-CT. The histological findings of the excised lymph nodes were then correlated with preoperative PET-CT imaging.<bold>Results: </bold>A median of 2.4 sentinel nodes were sampled per patient. No wound infections or chronic lymphedema occurred. SLNB identified tumors in 7 of the 28 patients (25%), including 3 patients who had normal PET-CT imaging of the nodal basin. In contrast, PET-CT demonstrated hypermetabolic regional nodes in 14 patients, and this resulted in a positive predictive value of only 29%. The sensitivity and specificity of PET-CT for detecting histologically confirmed nodal metastases were only 57% and 52%, respectively.<bold>Conclusions: </bold>SLNB can safely guide the rational selection of nodes for biopsy in pediatric and AYA sarcoma patients and can identify therapy-changing nodal disease not appreciated with PET-CT. Cancer 2017;155-160. © 2016 American Cancer Society. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0008543X
Volume :
123
Issue :
1
Database :
Complementary Index
Journal :
Cancer (0008543X)
Publication Type :
Academic Journal
Accession number :
120262643
Full Text :
https://doi.org/10.1002/cncr.30282